Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
about
Bisphosphonates in multiple myeloma: a network meta-analysisBisphosphonates and other bone agents for breast cancerBisphosphonates in multiple myelomaBisphosphonates for breast cancerZoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationOff-trial evaluation of bisphosphonates in patients with metastatic breast cancerPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerNational consensus in China on diagnosis and treatment of patients with advanced breast cancerBisphosphonates in breast cancerPain related to cancer treatments and diagnostic procedures: a no man's land?Biology of bone metastases.Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Use of intravenous bisphosphonates in older women with breast cancerDirect antitumour activity of zoledronic acid: preclinical and clinical data.Recent developments in bisphosphonates for patients with metastatic breast cancer.Analysis of orthopedic surgery of bone metastases in breast cancer patients.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Commentary: role of bone-modifying agents in metastatic breast cancer.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.Bisphosphonates in Breast Cancer Patients with Bone MetastasesPharmacoeconomic considerations in the treatment of breast cancer.Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasisIn vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeBone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian GuidelineBone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesBone-targeted agents in the treatment of lung cancer.Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ)Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumorsEfficacy and safety of ibandronate in the treatment of neoplastic bone disease.Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.Treatment of Bone Metastases in Patients with Advanced Breast Cancer.Bisphosphonates in breast cancer.Bisphosphonates and bone metastases: current status and future directions.Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-AnalysisBisphosphonates for metastatic bone pain.Ibandronate: efficacy in the treatment of metastatic bone disease.Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases.
P2860
Q24197839-585836DB-E782-4A23-845B-88ACF2618476Q24203656-FA723884-DB4F-49E8-91BA-57CF04CBD6A2Q24236776-0E6B516C-3202-45C6-BBC4-D3C26246100FQ24246519-BB0FA66C-FE07-4E4A-AA5C-BA5F60247319Q24650864-A7886F13-F2A9-494C-8DB3-7DE07EB3595CQ24811840-EF3F3F4F-2F2B-43E4-90BC-29A5E39B1410Q26746212-D7CF688F-6916-4212-9AE3-A52D26BED5CAQ26775621-417336A3-3DC0-4829-86FD-C559FA49BEC6Q26859326-0A6EE28E-F303-42D7-9A3D-CE0BDB3FDC80Q27026749-76365D7C-8921-44A5-92CB-6FBCC3CF2609Q27693653-007CF1EF-EEF3-4313-8AFC-03C6E75314C5Q28076646-50E3DDA7-835E-4E26-B0A2-6710E848DD74Q28087676-89AF5652-B77C-4B75-8CAB-4424293FB905Q33666930-A7FE631D-CB1F-4724-8169-0D94FB6F6591Q33850938-474160DE-1E65-493D-9758-4DC7B8CE06FBQ33935632-5A17CA04-E8EF-43AB-A9EC-A665A24CE300Q34488408-2741C9F0-8EDB-47A8-96D6-E17077868B94Q34583705-56D811AB-16F5-4DB4-88A0-BA8779C60135Q34638014-70420FAA-B5E9-4DBE-AEE9-3E9964DDA6F1Q34939979-14E665BA-5621-411D-A11D-3FBDDF15B217Q35050731-4FCFA9F6-842D-40B9-BD4A-73D04E23527DQ35095548-51E67B96-A5BB-4AEA-99A8-353BBA7AE0BCQ35205385-D3D4E983-4F00-49DE-AF99-CDA2D2AE3A51Q35345620-119E0844-395D-4918-8486-15E7F7DAA004Q35605757-854F641F-7DF9-477C-97B8-5EBCDD04ED6EQ35667196-4678CD6D-3084-485C-A799-4BB9D50A653FQ35750472-2C9CC315-D24F-4E59-8EC6-A069488F0771Q35750641-7CF6A93F-DDFD-4102-A488-4FD246503E9BQ35780792-82E505F9-821F-4A7B-8FDF-A3D323B1A792Q35884204-AE4C8DFC-73E3-46D2-9E21-49603857FAEBQ35905960-5187C52B-B670-4EA3-AD7C-DC582DE8D5E3Q35925543-64454D2C-26B8-4148-9A3B-C5EB862C0D7CQ35989786-3365537E-83E4-4938-8C01-64A9E104553BQ36036088-89145618-102F-4AFC-8B72-E18797BC4C29Q36085307-716B76AC-8399-4ECB-B063-756F3385C6A9Q36118409-ACF96C24-35E8-40DB-8E71-72A307133EA3Q36206819-1AD42F64-1E1D-42A3-9CF8-FECAD2D9232BQ36284022-3E390E50-D0F1-4782-8451-E8EBB9F2C4F0Q36429562-788596CB-903E-45AC-B563-B241A6A74B34Q36491383-BB1FAB1C-AFD5-4CF0-A2F9-D6D78FA04E2C
P2860
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Zoledronic acid is superior to ...... t least one osteolytic lesion.
@en
Zoledronic acid is superior to ...... t least one osteolytic lesion.
@nl
type
label
Zoledronic acid is superior to ...... t least one osteolytic lesion.
@en
Zoledronic acid is superior to ...... t least one osteolytic lesion.
@nl
prefLabel
Zoledronic acid is superior to ...... t least one osteolytic lesion.
@en
Zoledronic acid is superior to ...... t least one osteolytic lesion.
@nl
P2093
P356
P1433
P1476
Zoledronic acid is superior to ...... t least one osteolytic lesion.
@en
P2093
Bee-Lian Chen
David H Gordon
Joe Simeone
John Seaman
Lee S Rosen
Louise Provencher
Mary Kaminski
Peter D Eisenberg
Pierre Major
Robert E Coleman
P356
10.1002/CNCR.11892
P407
P577
2004-01-01T00:00:00Z